LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Beam Therapeutics Inc

Fermé

SecteurSoins de santé

16.84 -2.43

Résumé

Variation du prix de l'action

24h

Actuel

Min

16.65

Max

16.91

Chiffres clés

By Trading Economics

Revenu

-19M

-109M

Ventes

-23M

7.5M

BPA

-1.242

Marge bénéficiaire

-1,462.784

Employés

393

EBITDA

-29M

-114M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+162.21% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-218M

1.8B

Ouverture précédente

19.27

Clôture précédente

16.84

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Beam Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 sept. 2024, 14:20 UTC

Acquisitions, Fusions, Rachats

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Comparaison

Variation de prix

Beam Therapeutics Inc prévision

Objectif de Prix

By TipRanks

162.21% hausse

Prévisions sur 12 Mois

Moyen 44.13 USD  162.21%

Haut 80 USD

Bas 20 USD

Basé sur 16 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

16 ratings

13

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

16.225 / 20.17Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.